|
|
|
|
Imperial Innovations (AIM:IVO) increases stake in OSspray
Imperial Innovations (AIM: IVO, 'Imperial Innovations'), a leading technology commercialisation and investment company, has increased its stake in OSspray, an emerging speciality dental company, following a further drawdown of 980,000 under...
|
|
|
Ablynx Promoted to the Belgian Mid-Cap Index
- Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies, a novel class of antibody-derived therapeutic proteins, announced today its promotion to the Belgian Mid-Cap index (Bel Mid Index or BELMID) from 1...
|
|
|
BioInvent and ThromboGenics Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study w
- BioInvent International AB (OMXS: BINV) and ThromboGenics NV (Euronext Brussels: THR) announce that they have started recruitment of a second cohort of patients for their Phase II trial of TB-402.This follows completion of recruitment...
|
|
|
Illumina Launches Multi-Sample Indexing for GoldenGate(R) Assay
New Indexing Technology Offers Optimal Combination of Throughput and Cost for Low-Complexity Sample Screening SAN DIEGO- Jul.2, 2009-- Illumina, Inc. (NASDAQ:ILMN) today launched GoldenGate Indexing, a high-throughput genotyping...
|
|
|
IDBS Acquires InforSense to Provide End-to-End Solutions for Research & Development Data Management
- IDBS, a leading provider of innovative data management solutions to multinational R&D organizations, today announced that it has concluded an unconditional agreement to acquire InforSense Ltd (InforSense), a company providing award...
|
|
|
Increased demand drives Queensland Compound Library expansion
QCL capacity is increased by the acquisition of an additional comPOUND storage module Photo courtesy of Christopher Stacey, Griffith University June 22nd 2009 Queensland, Australia - Queensland Compound Library (QCL) today announced the...
|
|
|
Senexis To Collaborate With The Oxford Mrc Functional Genomics Unit And The University College London Mrc Cent
Cambridge, UK, 30th June 2009 - Inclusion Body Myositis (IBM) is the commonest acquired muscle disease affecting people over 50 years old and there is no effective treatment.Senexis Limited, the Oxford MRC Functional Genomics Unit (FGU)...
|
|
|
Malvern Mastersizer sales top the 10,000 mark
: Malvern, UK: Sales of Malvern Instruments' Mastersizer systems have exceeded the 10,000 instruments mark, a major milestone in the company's history.Now used by more than 90% of the world's leading chemical and pharmaceutical companies,...
|
|
|
IDT introduces Custom Labels - Personalized tube labels to help customers easily locate their oligos
Integrated DNA Technologies (IDT), the world leader in oligonucleotide synthesis, is the first company in the industry to introduce Custom Label Design to their website.With the Custom Label Design Tool, customers can tailor the...
|
|
|
Ablynx Announces a Novel Preclinical Development Candidate Targeting IL6R
ALX-0061 is a selective, low molecular weight biologic, binding to the IL6 receptor (IL6R).It has a very high potency and demonstrated a favourable PD, PK and safety profile in preclinical testing compared with the benchmark molecule.
|
